Frontlight ResearchEarly access
Taking people in PolandPhase 1
Continues OATD-02 treatment for people with advanced solid tumours
Tests OATD-02 in adults with advanced colorectal, ovarian, pancreatic or kidney cancer.
Key facts
- Who runs it
- Molecure S.A.
- Where
- Bydgoszcz, Otwock, and Warsaw, PolandSee the 3 sites
- Registry title
- An open-label, multicentre, rollover study to evaluate safety and antineoplastic activity of OATD-02 in patients with selected advances and/or metastatic solid tumours who completed the first-in-human study OATD-02-C-01
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 30 people, planned
- Started
- 23 Aug 2023
- Expected to end
- 7 Mar 2028
- Type of study
- Interventional
- Record updated
- 19 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic colorectal, ovarian, pancreatic or renal cell cancer who completed the first-in-human study OATD-02-C-01.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced and/or metastatic solid tumours: colorectal cancer, ovarian cancer, pancreatic cancer or renal cell carcinoma.
- Earlier treatment
- Must have completed the first-in-human study OATD-02-C-01.
Where in Poland
- Centrum Onkologii Im. Prof. Franciszka Lukaszczyka W BydgoszczyBydgoszcz, PolandTaking people
- Europejskie Centrum Zdrowia Otwock Sp. Z.o.o.Otwock, PolandTaking people
- LUX MED Onkologia Sp. z.o.o.Warsaw, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Continues OATD-02 treatment for people with advanced solid tumoursGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 19 February 2026